Type 1 diabetes (T1D) is a chronic illness that requires intensive lifelong management of blood glucose concentrations by means of external insulin administration. There have been substantial developments in the ways of measuring glucose levels, which is crucial to T1D self-management. Recently, continuous glucose monitoring (CGM) has allowed people with T1D to keep track of their blood glucose levels in near real-time. These devices have alarms that warn users about potentially dangerous blood glucose trends, which can often be shared with ther people. CGM is consistently associated with improved glycemic control and reduced hypoglycemia and is currently recommended by doctors. However, due to the costs of CGM, only those who qualify for hospital provision or those who can personally afford it are able to use it, which excludes many people. In this paper, I argue that unequal access to CGM results in: (1) unjust health inequalities, (2) relational injustice, (3) injustice with regard to agency and autonomy, and (4) epistemic injustice. These considerations provide prima facie moral reasons why all people with T1D should have access to CGM technology. I discuss the specific case of CGM policy in the Netherlands, which currently only provides coverage for a small group of people with T1D, and argue that, especially with additional considerations of cost-effectiveness, the Dutch government ought to include CGM in basic health care insurance for all people with T1D.

1 型糖尿病 (T1D) 是一种慢性疾病，需要通过外部胰岛素给药对血糖浓度进行终生强化管理。测量血糖水平的方法取得了重大进展，这对 T1D 自我管理至关重要。最近，连续血糖监测 (CGM) 使 T1D 患者能够近乎实时地跟踪他们的血糖水平。这些设备有警报，警告用户潜在危险的血糖趋势，通常可以与人们分享。CGM 始终与改善血糖控制和减少低血糖有关，目前被医生推荐。然而，由于CGM的成本，只有那些有资格获得医院供应的人或有能力负担的人才能使用它，这将很多人排除在外。在本文中，我认为对 CGM 的不平等获取会导致：（1）不公正的健康不平等，（2）关系不公正，（3）关于能动性和自主性的不公正，以及（4）认知上的不公正。这些考虑提供了为什么所有 T1D 患者都应该获得 CGM 技术的初步道德理由。我讨论了荷兰 CGM 政策的具体案例，该政策目前只为一小部分 T1D 患者提供保险，并认为，特别是在额外考虑成本效益的情况下，荷兰政府应该将 CGM 纳入基本医疗保健为所有 T1D 患者提供保险。这些考虑提供了为什么所有 T1D 患者都应该获得 CGM 技术的初步道德理由。我讨论了荷兰 CGM 政策的具体案例，该政策目前只为一小部分 T1D 患者提供保险，并认为，特别是在额外考虑成本效益的情况下，荷兰政府应该将 CGM 纳入基本医疗保健为所有 T1D 患者提供保险。这些考虑提供了为什么所有 T1D 患者都应该获得 CGM 技术的初步道德理由。我讨论了荷兰 CGM 政策的具体案例，该政策目前只为一小部分 T1D 患者提供保险，并认为，特别是在额外考虑成本效益的情况下，荷兰政府应该将 CGM 纳入基本医疗保健为所有 T1D 患者提供保险。